NCT04458259 is a Phase 1 clinical trial of PF-07265807 in Neoplasm Metastasis, sponsored by Pfizer.

Who is sponsoring NCT04458259?

NCT04458259 is sponsored by Pfizer.

What drugs are being tested in NCT04458259?

Interventions in NCT04458259: PF-07265807, Sasanlimab, Axitinib.

What condition does NCT04458259 study?

NCT04458259 studies Neoplasm Metastasis.

Is NCT04458259 still recruiting?

NCT04458259 is currently terminated. Last updated 28 August 2025.

Last reviewed 2025-08-28 · How we verify

NCT04458259

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Terminated Phase 1 Last updated 28 August 2025

What this trial tests

Phase 1 trial testing PF-07265807 in Neoplasm Metastasis in 88 participants. Terminated before completion.

Timeline

24 September 2020

Primary endpoint
15 November 2024

15 November 2024

Quick facts

Lead sponsor	Pfizer
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	88
Start date	24 September 2020
Primary completion	15 November 2024
Estimated completion	15 November 2024
Sites	33 locations across Spain, Japan, United States, Canada, Italy

Drugs / interventions tested

PF-07265807 (pf-07265807) — full drug profile →
Sasanlimab — full drug profile →
Axitinib — full drug profile →

Conditions studied

Neoplasm Metastasis — all drugs for Neoplasm Metastasis →

Sponsor

Pfizer — full company profile →

Who can join

18 and older, any sex, with Neoplasm Metastasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Drugging the efferocytosis process: concepts and opportunities.
Mehrotra P, Ravichandran KS. · · 2022 · cited 319× · PMID 35650427 · DOI 10.1038/s41573-022-00470-y
The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges.
Sang YB, Kim JH, Kim CG, Hong MH, et al · · 2022 · cited 45× · PMID 35311091 · DOI 10.3389/fonc.2022.811247
Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.
Peters S, Paz-Ares L, Herbst RS, Reck M. · · 2022 · cited 43× · PMID 35858709 · DOI 10.1136/jitc-2022-004863
AXL signaling in cancer: from molecular insights to targeted therapies.
Yadav M, Sharma A, Patne K, Tabasum S, et al · · 2025 · cited 42× · PMID 39924521 · DOI 10.1038/s41392-024-02121-7
The future of targeted kinase inhibitors in melanoma.
Caksa S, Baqai U, Aplin AE. · · 2022 · cited 25× · PMID 35513054 · DOI 10.1016/j.pharmthera.2022.108200
Immunotherapies Targeting Tumor-Associated Macrophages (TAMs) in Cancer.
Li MY, Ye W, Luo KW. · · 2024 · cited 24× · PMID 39065562 · DOI 10.3390/pharmaceutics16070865
Mertk: An emerging target in cancer biology and immuno-oncology.
Lahey KC, Gadiyar V, Hill A, Desind S, et al · · 2022 · cited 22× · PMID 35636929 · DOI 10.1016/bs.ircmb.2022.04.004
Mechanisms of immunity in acutely decompensated cirrhosis and acute-on-chronic liver failure.
Engelmann C, Zhang IW, Clària J. · · 2025 · cited 20× · PMID 37365995 · DOI 10.1111/liv.15644

Verify or expand the search:

Other recruiting trials for Neoplasm Metastasis

Currently open trials in the same condition.

NCT06912087 — Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC · Phase 1 · recruiting
NCT06534580 — Virtual Reality for Advanced Cancer Pain · active not recruiting
NCT06460961 — A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-68 · Phase 1 · active not recruiting
NCT05573893 — PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Dat · recruiting
NCT06046131 — Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression. · NA · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04458259 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 28 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04458259.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing